| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/24/2003 | US20030138457 Such as F protein of Paramyxovirus SV5 strain; this recombinant Rhabdovirus may express other non-Rhabdovirus attachment proteins and/or an enhancer protein; for diagnostic and therapeutic compositions for treatment of diseases |
| 07/24/2003 | US20030138433 Contacting isolated B-cell in vitro with a target antigen conjugate to produce target antigen manipulated B cells, fusing manipulated cells into the subject |
| 07/24/2003 | US20030138429 Compositions and methods for inhibiting metastasis |
| 07/24/2003 | US20030138422 Antibodies against growth and differentiation factor-8 (GDF-8), also known as myostatin, including fragments; muscle and bone degenerative disorders; muscular dystropy/atrophy; antidiabetic agents; congestive obstructive pulmonary disease |
| 07/24/2003 | US20030138421 Human Antibodies specific for interleukin 15 (IL-15) |
| 07/24/2003 | US20030138407 Therapeutic methods for nucleic acid delivery vehicles |
| 07/24/2003 | CA2841097A1 Albumin fusion proteins |
| 07/24/2003 | CA2706833A1 Geranyl compounds |
| 07/24/2003 | CA2706826A1 Geranyl compounds |
| 07/24/2003 | CA2700690A1 Process for producing reformatsky reagent in stable form |
| 07/24/2003 | CA2474239A1 Substituted pyridazinones as inhibitors of p38 |
| 07/24/2003 | CA2474151A1 Androgen regulated nucleic acid molecules and encoded proteins |
| 07/24/2003 | CA2474141A1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 07/24/2003 | CA2474002A1 Bispecific antibody dna constructs for intramuscular administration |
| 07/24/2003 | CA2473893A1 Stable salts of o-acetylsalicylic acid with basic amino acids ii |
| 07/24/2003 | CA2473570A1 Antisense compounds directed against human csf-1 |
| 07/24/2003 | CA2473447A1 Solid salts of benzazepine compounds and their use in the preparation of pharmaceutical compounds |
| 07/24/2003 | CA2473289A1 Asymmetric urea compounds useful as naaladase and psma imaging agents |
| 07/24/2003 | CA2473229A1 Selective melanin-concentrating hormone type -1 receptor agonists |
| 07/24/2003 | CA2473170A1 Therapeutic acridone and acridine compounds |
| 07/24/2003 | CA2473039A1 Novel anti-igf-ir antibodies and uses thereof |
| 07/24/2003 | CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| 07/24/2003 | CA2472619A1 Fused pyrimidine derivates as rho-kinase inhibitors |
| 07/24/2003 | CA2472204A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/24/2003 | CA2472168A1 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/24/2003 | CA2472160A1 Quinazolinone compounds in combined modalities for improved cancer treatment |
| 07/24/2003 | CA2471907A1 Antibody-avidin fusion proteins as cytotoxic drugs |
| 07/24/2003 | CA2471702A1 Human monoclonal antibodies against cd30 |
| 07/24/2003 | CA2471562A1 Tyrosyl derivatives and their use as p2x7 receptor modulators |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2471363A1 Albumin fusion proteins |
| 07/24/2003 | CA2471314A1 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| 07/24/2003 | CA2471309A1 Synthesis of combretastatin a-2 prodrugs |
| 07/24/2003 | CA2471192A1 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 07/24/2003 | CA2470649A1 Mmp inhibitors |
| 07/24/2003 | CA2469435A1 Modulators of lxr |
| 07/24/2003 | CA2464131A1 Compositions and methods for controlled release |
| 07/23/2003 | EP1329511A1 Polypeptide having phospholipase a2 actiivty |
| 07/23/2003 | EP1329508A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/23/2003 | EP1329504A1 Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like |
| 07/23/2003 | EP1329223A1 Expression potentiator for protein synthesis regulatory gene |
| 07/23/2003 | EP1329219A1 Apoptosis inducers, caspase cascade activators and anticancer agents |
| 07/23/2003 | EP1328816A2 Regulation of neutral development by daedalos |
| 07/23/2003 | EP1328653A2 Highly expressible genes |
| 07/23/2003 | EP1328646A2 Regulation of human adenylate cyclase, type iv |
| 07/23/2003 | EP1328635A2 Compositions and methods relating to lung specific genes |
| 07/23/2003 | EP1328634A2 Genes expressed in the cell cycle |
| 07/23/2003 | EP1328631A2 Her-2/neu fusion proteins |
| 07/23/2003 | EP1328630A2 Secreted proteins |
| 07/23/2003 | EP1328629A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 07/23/2003 | EP1328624A2 B7-like molecules and uses thereof |
| 07/23/2003 | EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 07/23/2003 | EP1328546A2 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 07/23/2003 | EP1328539A1 Vegf peptides and their use for inhibiting angiogenesis |
| 07/23/2003 | EP1328527A1 Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents |
| 07/23/2003 | EP1328522A2 Estrogen receptor modulators |
| 07/23/2003 | EP1328521A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 07/23/2003 | EP1328519A2 Orally active salts with tyrosine kinase activity |
| 07/23/2003 | EP1328516A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds |
| 07/23/2003 | EP1328513A2 Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| 07/23/2003 | EP1328511A1 Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| 07/23/2003 | EP1328510A2 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| 07/23/2003 | EP1328509A1 Methods of producing oxazolidinone compounds |
| 07/23/2003 | EP1328508A2 Propionic acid derivatives with ppar-alpha activating properties |
| 07/23/2003 | EP1328504A2 Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis |
| 07/23/2003 | EP1328319A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 07/23/2003 | EP1328298A1 Methods and compositions for modulating t cell activation and uses thereof |
| 07/23/2003 | EP1328296A2 Camptothecin conjugates |
| 07/23/2003 | EP1328293A2 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 07/23/2003 | EP1328291A2 Viruses targeted to hypoxic cells and tissues |
| 07/23/2003 | EP1328287A1 Compositions and methods for wt1 specific immunotherapy |
| 07/23/2003 | EP1328284A1 Novel medicinal herbal composition for treating liver diseases and hiv |
| 07/23/2003 | EP1328276A1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 07/23/2003 | EP1328272A1 Nf-kappa-b inhibitors |
| 07/23/2003 | EP1328267A2 Method of treating cancer using dithiocarbamate derivatives |
| 07/23/2003 | EP1328264A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 07/23/2003 | EP1328263A2 Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells |
| 07/23/2003 | EP1328262A2 A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes |
| 07/23/2003 | EP1328261A2 Treatment of neurodegenerative disease |
| 07/23/2003 | EP1328254A2 Lipid formulations for target delivery |
| 07/23/2003 | EP1328253A2 Administration of a thiol-based chemoprotectant compound |
| 07/23/2003 | EP1328236A2 Methods of decreasing or preventing pain using spicamycin derivatives |
| 07/23/2003 | EP1328151A2 Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer |
| 07/23/2003 | EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors |
| 07/23/2003 | EP1228073B1 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 07/23/2003 | EP1163246B1 Organic-arsenic compounds |
| 07/23/2003 | EP1148876A4 Calcilytic compounds |
| 07/23/2003 | EP1107741B1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 07/23/2003 | EP1079818B1 Composition comprising il-18 and topotecan for treatment and/or prevention of cancer |
| 07/23/2003 | EP1032575B1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 07/23/2003 | EP1001957B1 Macrolides with antitumor activity |
| 07/23/2003 | EP0956033B1 Total synthesis of the amino hip analogue of didemnin a |
| 07/23/2003 | EP0873137B1 Compositions including calcium influx blockers for inhibiting cell growth |
| 07/23/2003 | EP0814827B1 Vascular endothelial growth factor-b |
| 07/23/2003 | EP0811011B1 Carbohydrate conjugated bio-active compounds |
| 07/23/2003 | EP0743958B1 Avidin-biotin immunoconjugates |
| 07/23/2003 | CN1432068A Methods for ansamitocin prodn. method |
| 07/23/2003 | CN1432064A Bi-functional cancer treatment agents |
| 07/23/2003 | CN1432063A Humanised antibodies to epidermal growth factor receptor |
| 07/23/2003 | CN1432018A Crystalline and amorphous form of triazolo (4,5-d) pyrimidine compound |